Literature DB >> 7691624

Inhibition of neurogenic inflammation in the meninges by a non-peptide NK1 receptor antagonist, RP 67580.

S M Moussaoui1, L Philippe, N Le Prado, C Garret.   

Abstract

RP 67580, a non-peptide NK1 receptor antagonist, inhibited in a stereoselective and dose-dependent manner plasma extravasation caused in the dura mater by intravenous injection of capsaicin in guinea-pigs and of exogenous substance P in rats (ED50 = 35 and 2.5 micrograms/kg i.v., respectively). In the two species, RP 67580 appeared to be more effective in the dura mater than in the peripheral organs. These results indicate that selective NK1 receptor antagonists could be potentially effective for the treatment of migraine headache.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7691624     DOI: 10.1016/0014-2999(93)90879-m

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  10 in total

Review 1.  [Neuropeptide effects on the trigeminal system: pathophysiology and clinical significance for migraine].

Authors:  K Messlinger; M J M Fischer; J K Lennerz
Journal:  Schmerz       Date:  2011-08       Impact factor: 1.107

2.  Lack of a role for substance P in the control of dural arterial flow.

Authors:  J Carmody; M Pawlak; K Messlinger
Journal:  Exp Brain Res       Date:  1996-10       Impact factor: 1.972

3.  The pharmacology of GR203040, a novel, potent and selective non-peptide tachykinin NK1 receptor antagonist.

Authors:  D T Beattie; I J Beresford; H E Connor; F H Marshall; A B Hawcock; R M Hagan; J Bowers; P J Birch; P Ward
Journal:  Br J Pharmacol       Date:  1995-12       Impact factor: 8.739

4.  Reproducibility of the capsaicin-induced dermal blood flow response as assessed by laser Doppler perfusion imaging.

Authors:  B J Van der Schueren; J N de Hoon; F H Vanmolkot; A Van Hecken; M Depre; S A Kane; I De Lepeleire; S R Sinclair
Journal:  Br J Clin Pharmacol       Date:  2007-06-19       Impact factor: 4.335

5.  Blockade by oral or parenteral RPR 100893 (a non-peptide NK1 receptor antagonist) of neurogenic plasma protein extravasation within guinea-pig dura mater and conjunctiva.

Authors:  W S Lee; S M Moussaoui; M A Moskowitz
Journal:  Br J Pharmacol       Date:  1994-07       Impact factor: 8.739

6.  Increase of meningeal blood flow after electrical stimulation of rat dura mater encephali: mediation by calcitonin gene-related peptide.

Authors:  M Kurosawa; K Messlinger; M Pawlak; R F Schmidt
Journal:  Br J Pharmacol       Date:  1995-04       Impact factor: 8.739

Review 7.  Neurovascular contributions to migraine: Moving beyond vasodilation.

Authors:  Blaine Jacobs; Gregory Dussor
Journal:  Neuroscience       Date:  2016-06-14       Impact factor: 3.590

Review 8.  An update and systematic review on drug therapies for the treatment of refractory chronic cough.

Authors:  Nicole M Ryan; Anne E Vertigan; Surinder S Birring
Journal:  Expert Opin Pharmacother       Date:  2018-04-16       Impact factor: 3.889

9.  Enhancement of blood-tumor barrier permeability by Sar-[D-Phe8]des-Arg9BK, a metabolically resistant bradykinin B1 agonist, in a rat C6 glioma model.

Authors:  Ronie Cleverson Cardoso; Bruno Lobão-Soares; Marino Muxfeldt Bianchin; Carlos Gilberto Carlotti; Roger Walz; Márcio Alvarez-Silva; Andréa Gonçalves Trentin; Mauro Nicolau
Journal:  BMC Neurosci       Date:  2004-09-30       Impact factor: 3.288

Review 10.  Targeted CGRP Small Molecule Antagonists for Acute Migraine Therapy.

Authors:  Philip R Holland; Peter J Goadsby
Journal:  Neurotherapeutics       Date:  2018-04       Impact factor: 7.620

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.